In 2025, the Russian retail market for allergen-specific immunotherapy (ASIT) products (EphMRA group V01A) amounted to RUB 2.8 billion (at retail prices, including VAT). Over the year, Russian consumers purchased 257.3 thousand packs of these medicines. For the first time in several years, physical consumption of ASIT products declined: compared with 2024, pharmacy sales decreased by 6.5% in pack terms. At the same time, total consumer spending within the group increased by 8.5% year on year.

This divergence is largely explained by a high base effect, as 2024 was a record year for ASIT products. At that time, value sales increased by 65.6% compared with 2023, while physical consumption grew by 21.2%. In 2025, a decline in pack sales was observed for almost all brands present on the market, which are currently supplied exclusively by foreign manufacturers.

According to data from the RNC Pharma database Audit of Retail Sales of Medicines in Russia (total sell out), demand for allergen-specific immunotherapy products consistently increases during the winter months. This pattern is driven by the fact that most ASIT medicines are intended for the treatment of pollen allergies, and therapy must be initiated several months before the onset of the flowering season.

As in the previous year, the peak sales volume of ASIT products in 2025 was recorded in January. During this month, Russian consumers purchased ASIT medicines worth almost RUB 436 million. The second peak traditionally falls in December, when sales reached RUB 420.6 million. ASIT products are characterised by a high price level: in 2025, the average cost of a pack ranged from RUB 7,000 to RUB 15,000, depending on the number of doses and the stage of therapy. It is also important to note that ASIT is a long-term treatment method, typically lasting from three to five years and requiring maintenance therapy.

In the Russian retail pharmaceutical market, ASIT products are represented by two companies: Stallergenes and ALK-Abelló. The main share of physical sales volume is generated by the French product Staloral from Stallergenes. Despite positive value dynamics for this brand (+9% compared with 2024), its physical sales declined by 6%. A reduction in pack sales was also observed for other brands. In particular, the most pronounced decline was recorded for Ragwizax and Acarizax from ALK-Abelló, whose physical sales decreased by 34% and 15% respectively over the year.

An exception to the overall downward trend was Oralair by Stallergenes, indicated for the treatment of grass pollen allergy. In 2025, sales of this product increased by 45% in packs. However, this growth was largely attributable to very low sales volumes in 2024 and therefore reflects a recovery in demand rather than sustained expansion.

Figure. Dynamics of sales volumes and average prices of allergen-specific immunotherapy (ASIT) products on the Russian commercial retail market from January 2024 to December 2025